Senate passes wide‑ranging pharmacy bill; includes expanded access to naloxone and limits on listing pharmaceutical reps — controversial 'death‑penalty' sales条

Summary

A broad measure on prescription drugs and pharmacy regulation passed the Senate after amendments. The bill includes studies on access to mifepristone, expanded Narcan access rules, a provision to limit public listing of pharmaceutical representatives' personal information and new restrictions aimed at preventing in‑state supply of certain drugs when sold with knowledge they will be used to carry out executions — a provision that prompted significant debate about interstate commerce and was later narrowed in committee votes.